Post by
C10H12N2 on May 17, 2022 9:32am
Here They Go Again...Headed Over Another Steep Cliff
What kind of Phase 2 clinical trial does Algernon expect to conduct in Australia (AGAIN) where only 500 Thousand USD from the fire sale offering is allocated to conduct the combined IPF & Chronic Cough study? What it sure looks like to me is a study that will never end (AGAIN). More people to recruit in a country they know is scarce with patients and pursuing the sickest if patients by combining IPF to the study. Moreau told shareholders that IPF is not a disease most if not all other companies avoid attaching to a Chronic Cough study. Yet, there he goes again driving the bus towards another steep cliff. My guess is he will once again tell you it's fir "tax purposes". It's not about getting to results ASAP. You know, the type of results biotechs are suppose to put front and center. Like Bellus Health and their phase 2 standalone clinical trial(s) conducted in the USA? Bellus Health took all of less than a year from beginning to end to get to a data readout for its shareholders. Chronic Cough remains Algernon's best shot at substantially increased market cap and the company is running in the opposite direction with Phase 1 startups now being their focus. They know they will continue diluting the hell out of the company chasing after those Phase 1 studies versus keeping Chronic Cough the main thing. You are getting royally screwed here again and again and again in black and white.